Purine analog antimetabolite and tyrosine kinase inhibitor combination

This page covers all Purine analog antimetabolite and tyrosine kinase inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib).

Targets

Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib)

Phase 3 pipeline (1)

• Mercaptopurine, Imatinib · St. Jude Children's Research Hospital · Oncology
  Mercaptopurine and imatinib work together as a combination therapy: mercaptopurine is a purine analog that inhibits nucleotide synthesis to kill rapidly dividing cells, while imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases.

Patent intelligence

• purine analog antimetabolite and tyrosine kinase inhibitor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates